S&P Futures
4,020.25 +19.00 (+0.47%) Dow Futures
32,565.00 +131.00 (+0.40%) Nasdaq Futures
12,945.25 +55.00 (+0.43%) Russell 2000 Futures
1,759.30 +11.60 (+0.66%) Crude Oil
69.42 +0.16 (+0.23%) Gold
1,974.20 -9.60 (-0.48%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 69.01 |
| Open | 68.70 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 68.53 - 70.50 |
| 52 Week Range | 49.70 - 81.57 |
| Volume | |
| Avg. Volume | 2,581,708 |
| Market Cap | 18.446B |
| Beta (5Y Monthly) | 0.77 |
| PE Ratio (TTM) | 14.96 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.98 (2.53%) |
| Ex-Dividend Date | Dec 30, 2022 |
| 1y Target Est | N/A |
- PR Newswire
Swisslog's robotic fulfillment system and software to support new Cardinal Health at-Home Solutions distribution center
Swisslog, a leading provider of best-in-class warehouse automation and software, has announced that Cardinal Health (NYSE: CAH) will install a Swisslog Automation Solution within its new at-Home Solutions distribution center in Grove City, Ohio. The facility is part of the at-Home Solutions business' multi-year strategy to increase warehouse capacity to accommodate its rapid growth.
- PR Newswire
Cardinal Health's Outcomes™ collaborates with Signify Health to offer in-home medication therapy management
Cardinal Health (NYSE:CAH) today announced its collaboration with Signify Health (NYSE:SGFY) to offer in-home clinical and medication management services through its Outcomes™ business. This collaboration will help reduce costs and eliminate gaps in care for more than 2.3 million members nationwide to support their treatment journey from prescription to pharmacy to home.
- PR Newswire
New Cardinal Health report examines shifts in biosimilars industry
Today, Cardinal Health (NYSE: CAH) released its 2023 Biosimilars Report: Tracking market expansion and sustainability amidst a shifting industry, a publication that highlights provider perceptions, utilization and the latest market trends of biosimilars. The report assesses new and changing perspectives regarding some of the most disruptive biosimilars launched in the areas of immunology and ophthalmology, noting a growing familiarity of the medications among rheumatologists with 76% reporting b
